Celldex Therapeutics Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has completed patient enrollment for its Phase 2 clinical study of barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Current treatment options for CSU are limited and there are no approved therapies for patients who do not respond to omalizumab.
July 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Completion of patient enrollment for Celldex's Phase 2 study of barzolvolimab could potentially lead to a new treatment option for CSU, which currently has limited therapies.
The completion of patient enrollment indicates progress in the development of barzolvolimab. If the study results are positive, it could lead to a new treatment option for CSU, potentially boosting Celldex's market position and stock value.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100